We recently published an article titled Why These 15 Biotech Stocks Are Skyrocketing So Far In 2025. In this article, we are ...

We recently published a list of the 10 Best Performing Pharma Stocks So Far in 2025. In this article, we are going to take a ...

NEW YORK CITY, NY / ACCESS Newswire / March 4, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on ...

In a report released yesterday, Liisa Bayko from Evercore ISI maintained a Buy rating on Akero Therapeutics (AKRO – Research Report), with a ...

Shares of AKRO stock opened at $45.54 on Monday. The stock’s 50-day moving average is $39.27 and its 200 day moving average is $32.78. Akero Therapeutics has a 1-year low of $17.86 and a 1-year ...

89bio Inc . (NASDAQ:ETNB) Trades Lower in Sympathy with Akero Therapeutics (NASDAQ:AKRO) Akero -63% Following NASH DataETNB -40% ByInvesting.com • Oct 10, 2023 Akero Therapeutics Falls 48% ...

Feb. 28, 2025 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic disease marked by ...

Y Intercept Hong Kong Ltd lessened its stake in Akero Therapeutics, Inc. (NASDAQ:AKRO – Free Report) by 47.1% in the fourth ...

Akero Therapeutics announced a public offering of over 5.3 million shares at $48 each, aiming for $350 million in proceeds. Akero Therapeutics, Inc. has announced a public offering of 5,333,420 ...

Explore Akero Therapeutics stock price, quotes, charts and forecasts with Benzinga. Stay updated on market trends for AKRO. Akero Therapeutics, Brinker International And Viavi Are Among Top Mid ...

In this article, we are going to take a look at where Akero Therapeutics, Inc. (NASDAQ:AKRO) stands against the other biotech stocks. No matter the market environment, you’ll always find ...

Reported unprecedented, statistically significant reversal of compensated cirrhosis (F4) due to MASH after 96 weeks of ...